Journal of Pain and Symptom Management
Volume 38, Issue 5 , Pages 683-690 , November 2009

Methylnaltrexone Treatment of Opioid-Induced Constipation in Patients with Advanced Illness

  • Bruce H. Chamberlain, MD

      Affiliations

    • Palliative Consulting LLC, Orem, Utah, USA
    • Corresponding Author InformationAddress correspondence to: Bruce H. Chamberlain, MD, Palliative Consulting LLC, 1927 N. Skyline Drive, Orem, UT 84097, USA.
    • ,
  • Karen Cross, MD

      Affiliations

    • Hospice & Palliative Care Center, Winston-Salem, North Carolina, USA
    • ,
  • Jaron L. Winston, MD

      Affiliations

    • Senior Adult Specialty Healthcare, Austin, Texas, USA
    • ,
  • Jay Thomas, MD

      Affiliations

    • City of Hope National Medical Center, Duarte, California, USA
    • ,
  • Wenjin Wang, PhD

      Affiliations

    • Wyeth Pharmaceuticals, Collegeville, Pennsylvania, USA
    • ,
  • Chinyu Su, MD

      Affiliations

    • Wyeth Pharmaceuticals, Collegeville, Pennsylvania, USA
    • ,
  • Robert J. Israel, MD

      Affiliations

    • Progenics Pharmaceuticals, Inc., Tarrytown, New York, USA

,Accepted 3 March 2009.

  • Image Result

    a)Rescue-free laxation response rates within four hours post-dosing among responders to all previous doses, ITT patients who had doses up to current dose being analyzed. ∗P=0.023 vs. placebo. b)Rescue

    a)Rescue-free laxation response rates within four hours post-dosing among responders to all previous doses, ITT patients who had doses up to current dose being analyzed. ∗P=0.023 vs. placebo. b)Rescue-free laxation response rates within four hours post-dosing among nonresponders to all previous doses, ITT patients who had doses up to current dose being analyzed. ∗P=0.006 vs. placebo.

 This research was supported by Progenics Pharmaceuticals, Inc. Drs. K.C., J.L.W., and J.T. report receiving lecture and/or consulting fees from Wyeth Pharmaceuticals; Drs. W.W. and C.S. report being employees of Wyeth Pharmaceuticals and having an equity interest in the company; and Dr. R.J.I. reports being an employee of Progenics Pharmaceuticals and having an equity interest in the company. No other potential conflict of interest relevant to this article was reported.

PII: S0885-3924(09)00641-1

doi: 10.1016/j.jpainsymman.2009.02.234

Journal of Pain and Symptom Management
Volume 38, Issue 5 , Pages 683-690 , November 2009

Article Tools

* Image Usage & Resolution